Oncolytic viruses (OVs) are emerging as a promising therapeutic approach for treating cancer. OVs are capable of both tumor-specific cell lysis and immune stimulation and can be optimized for enhanced tumor selectivity.  WuXi AppTec offers a comprehensive platform of OV-related services, including virus engineering and validation, immune profiling and lysis assays, tumor cell selectivity assays, …Read More >

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

WuXi AppTec scientists contributed to a study which identified a novel, indole-based, selective estrogen receptor degrader (SERD), designated LX-039. The authors show that LX-039 exhibits potent activity in ER degradation and proliferation assays. With favorable ADME/PK properties, LX-039 also exhibits higher efficacy in a tamoxifen-resistant MCF7 CDX model compared to fulvestrant, with up to 90% inhibition …Read More >

WuXi AppTec scientists recently contributed to a research article in Cell Chemical Biology demonstrating the successful conversion of ligands identified from DNA-encoded library (DEL) screening into highly functional, cell-active, bioluminescence resonance energy transfer (BRET) probes. The authors show that analyzing preliminary DEL hits based on target occupancy data generated in live, intact cells is an …Read More >

Leverage our panel of in vitro immunology assays to accelerate your lead optimization efforts.  WuXi AppTec offers a comprehensive platform of immune profiling services, including ligand/receptor binding for target validation and cell-based functional assays to characterize both innate and adaptive immune responses. Our end-to-end services panel includes suppressive assays, mixed lymphocyte reactions, mast cell degranulation assays, …Read More >

WuXi AppTec offers a full range of services to characterize bispecific antibodies and bispecific T cell engagers (BiTEs).  Our comprehensive platform includes cell line selection and target expression, assessment of binding affinity (SPR, flow cytometry), in vitro activity testing (T cell activation, cytokine release, cytotoxicity), and evaluation of in vivo efficacy (using HSC and PBMC …Read More >

Lysosomal storage disorders (LSDs) are rare genetic conditions that cause a buildup of toxic materials in the cells of various organs.  As part of our rare disease models platform, WuXi AppTec offers an extensive panel of LSD mouse models, including Gaucher disease, Pompe disease, Fabry disease, and Hurler syndrome (MPS I).  Our service platform supports …Read More >

To accelerate screening and lead optimization efforts involving immune cell differentiation, WuXi AppTec offers a comprehensive CD34+ hematopoietic stem cell differentiation platform.  Our panel includes neutrophil, eosinophil, erythroid, and mast cell differentiation, as well as monocyte/macrophage differentiation and polarization, and megakaryocyte/platelet differentiation. Check out our comprehensive platform of immune profiling and biomarker services

WuXi AppTec scientists collaborated on a study to characterize a series of pyrroloquinoline derivatives that were designed and synthesized to understand the effect of various substitutions on human cytomegalovirus (HCMV) polymerase activity, antiviral activity, and hERG inhibition.  Results suggest that substitutions can be fine-tuned to reduce hERG inhibition while maintaining HCMV antiviral potency. The abstract …Read More >